VIM

Vimentin · P08670 · VIM on Sugi Atlas →

18 patent compounds predicted against VIM, 8 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL24162713 SCHEMBL24162713 0.59 1/20
SCHEMBL25978478 SCHEMBL25978478 0.57 1/20
SCHEMBL29365901 SCHEMBL29365901 0.56 1/20
SCHEMBL25978481 SCHEMBL25978481 0.54 1/20
SCHEMBL12754797 SCHEMBL12754797 0.49 1/20
SCHEMBL13671131 SCHEMBL13671131 0.49 1/20
SCHEMBL20906815 SCHEMBL20906815 0.44 1/20
SCHEMBL20906849 SCHEMBL20906849 0.41 1/20

Clinical trials — most relevant to VIM by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation PHASE3COMPLETED
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer PHASE2COMPLETED
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. PHASE2WITHDRAWN
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer PHASE1COMPLETED
Acid Reflux and Stromal Fibroblasts in Barrett's Esophagus PHASE1COMPLETED
Epithelial Mesenchymal Transition and Periodontitis nanUNKNOWN
Diagnostic Value of Anti-MCV in Pts With RA nanUNKNOWN
Diagnostic Utility of Anti MCV Antibodies,Anti CCPantibodies and RF in RA nanUNKNOWN
Expression of Epithelial-Mesenchymal Transition Associated Markers in Peri-implant Tissues nanRECRUITING
Epithelial Mesenchymal Transition Markers in OSMF nanCOMPLETED
Circulating Tumor Cell Reducing No-touch Nephrectomy nanCOMPLETED
Impact of Molecular Pathological And Clinical Features for Adjuvant Treatment Selection in Endometrial Cancer: Asian Registry nanACTIVE_NOT_RECRUITING
Influence of EMT on CTCs and Disease Progression in Prostate Cancer nanCOMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA nanRECRUITING
VETC, Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Carcinoma nanUNKNOWN
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study nanCOMPLETED
Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors nanCOMPLETED
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET) nanCOMPLETED
Prospective Breast Cancer Biobanking nanENROLLING_BY_INVITATION
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer nanNOT_YET_RECRUITING
Biomarkers in the Diagnosis and Prognosis of NAFLD nanRECRUITING
EMT in Peritoneal Dialysis Patients nanCOMPLETED
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer nanCOMPLETED
Prognostic Value of Liver Cancer CTCs Isolated by a Novel Microfluidic Platform nanUNKNOWN
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis nanCOMPLETED
Evaluation of Lymph Node Analysis Using One Step Nucleic Acid Amplification (OSNA) in Patients With Lung Cancer Who Underwent Robotic Lung Resection, Comparison With Traditional Methods nanENROLLING_BY_INVITATION
Role of Nox2 in CNI-induced Renal Fibrosis nanCOMPLETED
Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer nanUNKNOWN
Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a VIM binder may also engage these)

ProteinNameSimilarity
Q4R4X4 1.000 Q4R4X4 →
P48616 1.000 P48616 →
Q04948 1.000 Q04948 →
P84198 1.000 P84198 →
P02543 1.000 P02543 →
P48676 1.000 P48676 →
P05784 1.000 P05784 →
P31001 1.000 P31001 →
Q6P864 1.000 Q6P864 →
Q5R1W8 1.000 Q5R1W8 →
P09654 1.000 P09654 →
P48670 1.000 P48670 →
P24789 1.000 P24789 →
P08802 1.000 P08802 →
Q92155 1.000 Q92155 →
A0A8C0N8E3 1.000 A0A8C0N8E3 →
P35617 1.000 P35617 →
P20152 1.000 P20152 →
P48674 1.000 P48674 →
P31000 1.000 P31000 →
P02544 1.000 P02544 →
Q7Z3Y8 1.000 Q7Z3Y8 →
P02540 1.000 P02540 →
Q58EE9 1.000 Q58EE9 →
P08776 0.999 P08776 →
Q5R8S9 0.999 Q5R8S9 →
Q5RA72 0.998 Q5RA72 →
P07196 0.998 P07196 →
Q6IG12 0.998 Q6IG12 →
Q90303 0.998 Q90303 →